Literature DB >> 25408841

Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors.

Md Jashim Uddin1, Anna V Elleman1, Kebreab Ghebreselasie1, Cristina K Daniel1, Brenda C Crews1, Kellie D Nance1, Tamanna Huda1, Lawrence J Marnett1.   

Abstract

We report the design and synthesis of fluorine-containing cyclooxygenase-1 (COX-1)-selective inhibitors to serve as prototypes for the development of a COX-1-targeted imaging agent. Deletion of the SO2CH3 group of rofecoxib switches the compound from a COX-2- to a COX-1-selective inhibitor, providing a 3,4-diarylfuran-2(5H)-one scaffold for structure-activity relationship studies of COX-1 inhibition. A wide range of fluorine-containing 3,4-diarylfuran-2(5H)-ones were designed, synthesized, and tested for their ability to selectively inhibit COX-1 in purified protein and human cancer cell assays. Compounds containing a fluoro-substituent on the C-3 phenyl ring and a methoxy-substituent on the C-4 phenyl ring of the 3,4-diarylfuran-2(5H)-one scaffold were the best COX-1-selective agents of those evaluated, exhibiting IC50s in the submicromolar range. These compounds provide the foundation for development of an agent to facilitate radiologic imaging of ovarian cancer expressing elevated levels of COX-1.

Entities:  

Keywords:  Cyclooxygenase-1 (COX-1); furanone; imaging; rofecoxib; structure−activity relationship

Year:  2014        PMID: 25408841      PMCID: PMC4233350          DOI: 10.1021/ml500344j

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  30 in total

Review 1.  Cyclooxygenases: structural, cellular, and molecular biology.

Authors:  W L Smith; D L DeWitt; R M Garavito
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

2.  Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.

Authors:  Md Jashim Uddin; Brenda C Crews; Anna L Blobaum; Philip J Kingsley; D Lee Gorden; J Oliver McIntyre; Lynn M Matrisian; Kotha Subbaramaiah; Andrew J Dannenberg; David W Piston; Lawrence J Marnett
Journal:  Cancer Res       Date:  2010-05-01       Impact factor: 12.701

3.  [Pharmacological profile of mofezolac, a new non-steroidal analgesic anti-inflammatory drug].

Authors:  N Ono; N Yamamoto; A Sunami; Y Yamasaki; H Miyake
Journal:  Nihon Yakurigaku Zasshi       Date:  1990-02

4.  Principal involvement of cyclooxygenase-1-derived prostaglandins in the c-fos expression of the rat hind brain following visceral stimulation with acetic acid.

Authors:  H Kusuhara; A Fukunari; H Matsuyuki; T Okumoto
Journal:  Brain Res Mol Brain Res       Date:  1997-12-01

5.  Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer.

Authors:  Md Jashim Uddin; Brenda C Crews; Kebreab Ghebreselasie; Imran Huda; Philip J Kingsley; Mohammad Sib Ansari; Mohammed N Tantawy; Jeffery Reese; Lawrence J Marnett
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-07

6.  The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models.

Authors:  T Ochi; Y Motoyama; T Goto
Journal:  Eur J Pharmacol       Date:  2000-03-10       Impact factor: 4.432

7.  Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer.

Authors:  Rajnish A Gupta; Lovella V Tejada; Beverly J Tong; Sanjoy K Das; Jason D Morrow; Sudhansu K Dey; Raymond N DuBois
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

8.  Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal.

Authors:  Leonardo Di Nunno; Paola Vitale; Antonio Scilimati; Stefania Tacconelli; Paola Patrignani
Journal:  J Med Chem       Date:  2004-09-23       Impact factor: 7.446

9.  Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer.

Authors:  Takiko Daikoku; Susanne Tranguch; Anindita Chakrabarty; Dingzhi Wang; Dineo Khabele; Sandra Orsulic; Jason D Morrow; Raymond N Dubois; Sudhansu K Dey
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

10.  Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.

Authors:  Andy J Liedtke; Brenda C Crews; Cristina M Daniel; Anna L Blobaum; Philip J Kingsley; Kebreab Ghebreselasie; Lawrence J Marnett
Journal:  J Med Chem       Date:  2012-02-14       Impact factor: 7.446

View more
  4 in total

1.  Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6).

Authors:  Gino Cingolani; Andrea Panella; Maria Grazia Perrone; Paola Vitale; Giuseppe Di Mauro; Cosimo G Fortuna; Roger S Armen; Savina Ferorelli; William L Smith; Antonio Scilimati
Journal:  Eur J Med Chem       Date:  2017-06-24       Impact factor: 6.514

2.  Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer.

Authors:  Andrew J Wilson; Oluwole Fadare; Alicia Beeghly-Fadiel; Deok-Soo Son; Qi Liu; Shilin Zhao; Jeanette Saskowski; Md Jashim Uddin; Cristina Daniel; Brenda Crews; Brian D Lehmann; Jennifer A Pietenpol; Marta A Crispens; Lawrence J Marnett; Dineo Khabele
Journal:  Oncotarget       Date:  2015-08-28

3.  Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.

Authors:  Md Jashim Uddin; Andrew J Wilson; Brenda C Crews; Paola Malerba; Md Imam Uddin; Philip J Kingsley; Kebreab Ghebreselasie; Cristina K Daniel; Michael L Nickels; Mohammed N Tantawy; Elma Jashim; H Charles Manning; Dineo Khabele; Lawrence J Marnett
Journal:  ACS Omega       Date:  2019-05-24

4.  Conservative Secondary Shell Substitution In Cyclooxygenase-2 Reduces Inhibition by Indomethacin Amides and Esters via Altered Enzyme Dynamics.

Authors:  Mary E Konkle; Anna L Blobaum; Christopher W Moth; Jeffery J Prusakiewicz; Shu Xu; Kebreab Ghebreselasie; Dapo Akingbade; Aaron T Jacobs; Carol A Rouzer; Terry P Lybrand; Lawrence J Marnett
Journal:  Biochemistry       Date:  2015-12-31       Impact factor: 3.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.